109 related articles for article (PubMed ID: 12391375)
1. Cladribine in the treatment of IgM paraproteinemic polyneuropathy.
Ghosh A; Littlewood T; Donaghy M
Neurology; 2002 Oct; 59(8):1290-1. PubMed ID: 12391375
[No Abstract] [Full Text] [Related]
2. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.
Niermeijer JM; Eurelings M; Lokhorst H; Franssen H; Fijnheer R; Wokke JH; Notermans NC
Neurology; 2006 Dec; 67(11):2076-9. PubMed ID: 17159126
[TBL] [Abstract][Full Text] [Related]
3. Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy.
Stork AC; Cats EA; Vlam L; Heezius E; Rooijakkers S; Herpers B; de Jong BA; Rijkers G; van Strijp J; Notermans NC; van den Berg LH; van der Pol WL
J Neuroimmunol; 2016 Jan; 290():76-9. PubMed ID: 26711574
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy.
Stork AC; Jacobs BC; Tio-Gillen AP; Eurelings M; Jansen MD; van den Berg LH; Notermans NC; van der Pol WL
J Neuroimmunol; 2014 Mar; 268(1-2):89-94. PubMed ID: 24529728
[TBL] [Abstract][Full Text] [Related]
5. Intravenous cyclophosphamide in refractory polyneuropathy associated with IgM monoclonal gammopathy: an uncontrolled open trial.
Hamidou MA; Belizna C; Wiertlewsky S; Audrain M; Biron C; Grolleau JY; Mussini JM
Am J Med; 2005 Apr; 118(4):426-30. PubMed ID: 15808143
[No Abstract] [Full Text] [Related]
6. Long-term effect of rituximab in anti-mag polyneuropathy.
Benedetti L; Briani C; Franciotta D; Carpo M; Padua L; Zara G; Zambello R; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
Neurology; 2008 Nov; 71(21):1742-4. PubMed ID: 19015493
[No Abstract] [Full Text] [Related]
7. Paraproteins in the spinal fluid of patients with paraproteinemic polyneuropathies.
Dalakas MC; Papadopoulos NM
Ann Neurol; 1984 Jun; 15(6):590-3. PubMed ID: 6430213
[TBL] [Abstract][Full Text] [Related]
8. Marked increase in serum IgM during treatment of Waldenstrom's macroglobulinemia with cladribine.
Krishna VM; Carey RW; Bloch KJ
N Engl J Med; 2003 May; 348(20):2045-6. PubMed ID: 12748329
[No Abstract] [Full Text] [Related]
9. Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups.
Ilyas AA; Quarles RH; Dalakas MC; Fishman PH; Brady RO
Ann Neurol; 1985 Dec; 18(6):655-9. PubMed ID: 2417543
[TBL] [Abstract][Full Text] [Related]
10. Hairy cell leukaemia complicated by anti-MAG paraproteinemic demyelinating neuropathy: resolution of neurological syndrome after cladribrine treatment.
Rossi D; Franceschetti S; Cerri M; Conconi A; Lunghi M; Capello D; Cantello R; Gaidano G
Leuk Res; 2007 Jun; 31(6):873-6. PubMed ID: 17007925
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
12. [Muscle weakness, polyneuropathy].
Seitzer B; Spieker C; Zidek W; Vetter H
Schweiz Rundsch Med Prax; 1987 Mar; 76(14):380-2. PubMed ID: 3589294
[No Abstract] [Full Text] [Related]
13. Immunoglobulins in chronic inflammatory demyelinating polyneuropathy.
Comi G; Quattrini A; Fazio R; Roveri L
Neurol Sci; 2003 Oct; 24 Suppl 4():S246-50. PubMed ID: 14598053
[TBL] [Abstract][Full Text] [Related]
14. [Polyneuropathies and dysglobulinemias].
Ferrer S; Jiménez C
Rev Med Chil; 1994 Apr; 122(4):448-53. PubMed ID: 7809541
[TBL] [Abstract][Full Text] [Related]
15. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; van der Linden MW; Lokhorst HM; Franssen H; Fischer K; Teunissen LL; van den Berg LH; Schobben F; Wokke JH; Notermans NC
Neurology; 2007 Jul; 69(1):50-9. PubMed ID: 17606880
[TBL] [Abstract][Full Text] [Related]
16. Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy.
Eurelings M; Ang CW; Notermans NC; Van Doorn PA; Jacobs BC; Van den Berg LH
Neurology; 2001 Nov; 57(10):1909-12. PubMed ID: 11723289
[TBL] [Abstract][Full Text] [Related]
17. Treatment of IgM antibody associated polyneuropathies using rituximab.
Pestronk A; Florence J; Miller T; Choksi R; Al-Lozi MT; Levine TD
J Neurol Neurosurg Psychiatry; 2003 Apr; 74(4):485-9. PubMed ID: 12640069
[TBL] [Abstract][Full Text] [Related]
18. [Clinicoelectrophysiological characteristics of peripheral nerves with paraproteinemia].
Tang H; Zhang Z
Zhonghua Yi Xue Za Zhi; 2015 Jan; 95(4):283-5. PubMed ID: 25877245
[TBL] [Abstract][Full Text] [Related]
19. Level of SH groups in paraproteinemic sera.
Tichý M; Hrncír Z
Neoplasma; 1975; 22(5):531-4. PubMed ID: 1196436
[TBL] [Abstract][Full Text] [Related]
20. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.
Notermans NC; Lokhorst HM; Franssen H; Van der Graaf Y; Teunissen LL; Jennekens FG; Van den Berg LH; Wokke JH
Neurology; 1996 Nov; 47(5):1227-33. PubMed ID: 8909434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
